T. Rowe Price Investment Management
NBIX icon

T. Rowe Price Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

T. Rowe Price Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,008,326
Closed -$107M – 558
2022
Q3 		$107M Buy
+1,008,326
New +$102M 0.09% 229

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Investment Management's NBIX Position: Q4 2022 in Review

T. Rowe Price Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 1,008,326 shares — an estimated $107M sold.

T. Rowe Price Investment Management first reported a position in NBIX in Q3 2022 and held it in 1 quarter. The position peaked at $107M in Q3 2022. 530 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • T. Rowe Price Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,008,326 Neurocrine Biosciences shares in Q4 2022, an estimated $107M.
  • T. Rowe Price Investment Management first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 1 quarter.
  • T. Rowe Price Investment Management's Neurocrine Biosciences position peaked at $107M in Q3 2022.
  • 530 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.